Diabetes drug after heart attack
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a diabetes medication can improve artery health and heart function after a heart attack. It is for people who have had a STEMI and also have diabetes or a weakened heart pump.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had a specific type of heart attack called a STEMI.
- You also need to have either type 2 diabetes or a weak heart pump (ejection fraction below 40%).
- Your kidneys must be working well (eGFR above 60).
- You cannot have active cancer, autoimmune disease, severe liver disease, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
This study tests whether a diabetes medication called ertugliflozin can help protect your heart function after a heart attack. Researchers want to see if starting this medicine early (within 3 days) helps your heart recover better.
This study measures how your body handles sugar and related hormones in people after a new STEMI heart attack, and compares them with people who do not have diabetes or have prediabetes. The goal is to better understand metabolic changes after the event, which could help future care.
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
This study looks at how insulin resistance affects blood flow after a common heart attack procedure (stenting) in people with type 2 diabetes. It may help doctors understand why some patients have poor blood flow after treatment.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
Hear when a new Myocardial Infarction (MI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.